1885.30
-4.53%
Emkay
MHL announced its acquisition of Core Diagnostics—an oncology focused diagnostics chain with majority of its revenue derived from North/East India— for Rs2.47bn, thus valuing the company at ~2.24x EV/Sales on FY24 revenue
Emkay decreased Buy price target of Metropolis Healthcare Ltd. to 2050.0 on 02 Jul, 2025.
More from Metropolis Healthcare Ltd.
Recommended